AIMS Cancer Outcomes Study
Advanced Integrative Oncology Treatment for Adult and Pediatric Patients With Cancer: A Prospective Outcomes Study
Advanced Integrative Medical Science Institute
500 participants
May 18, 2020
OBSERVATIONAL
Conditions
Summary
The overall aim is to describe disease-free survival (DFS) in early stage cancer patients and three-year overall survival (OS) outcomes in advanced stage cancer patients receiving Advanced Integrative Oncology (AIO) treatment in a prospective consecutive case series outcomes study. We will collect data and study outcomes for patients with cancer who receive care at AIMS Institute.
Eligibility
Inclusion Criteria5
- A new patient coming in for a first office call (FOC) or first consultation via telemedicine with a diagnosis of cancer, or
- An established patient with a diagnosis of cancer receiving treatment at the AIMS Institute;
- If over 18 years of age are able to understand study design adequately and provide signed informed consent (IC) to enrollment;
- If younger than 18 years of age informed assent from the child and informed consent from a parent or guardian who is able to understand the study design adequately and provide signed informed consent for the pediatric patient;
- A confirmed diagnosis of cancer based on medical oncology medical records.
Exclusion Criteria4
- Patients not diagnosed with cancer;
- Telehealth patients;
- Cannot read or understand English well enough to read and sign the consent form and complete the questionnaires;
- Unwilling to participate in the AIMS Institute observational study.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04495790